Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD95 Purified Low Endotoxin

Anti-Hu CD95 Purified Low Endotoxin

Anti-Hu CD95 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD95
Clone
EOS9.1
Format
Purified Low Endotoxin
Reactivity
Human
Application
FC (QC tested), FUNC
Variant
0.1 mg
12-753-C100
In stock
0.00 USD
Variant
0.1 mg
11-261-C100
In stock
0.00 USD
Contact distributor
Product details
References
Isotype
Mouse IgM kappa
Specificity
The mouse monoclonal antibody EOS9.1 recognizes an extracellular epitope of CD95 (Fas/APO-1), a 46 kDa glycoprotein of the tumour necrosis factor/nerve growth factor (TNF/NGF) receptor superfamily, expressed on a variety of normal and neoplastic cells.
Application
FC (QC tested), FUNC
Reactivity
Human
Immunogen
P815 cells transfected with human CD95
Other names
FAS1, APT1, APO-1, FASTM, ALPS1A, TNFRSF6
Concentration
1 mg/ml
Preparation
Purified by precipitation and chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

General references:

Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP: Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide. Exp Cell Res. 2008 Feb 1;314(3):554-63.
PubMed
Guo Z, Zhang M, Tang H, Cao X: Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood. 2005 Sep 15;106(6):2033-41.
PubMed
Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC: Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol. 2003 Jun 15;170(12):6209-16.
PubMed
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998 Mar 16;17(6):1675-87.
PubMed

Product specific references:

Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK: Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol. 2003 Feb;5(2):118-25.
PubMed
Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J: Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May;120(5):1479-93
PubMed
Kasper HU, Konze E, Kern M, Stippel DL: CD95 and TNFα-induced apoptosis in liver metastases of colorectal carcinoma. In Vivo. 2010 Sep-Oct;24(5):653-7.
PubMed
Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ, Frauwirth KA, Zhang L, Katsaros D, Thompson CB, Levine B, Coukos G: Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res. 2004 Mar 15;64(6):2175-82.
PubMed
Variant
0.1 mg
12-753-C100
In stock
0.00 USD
Variant
0.1 mg
11-261-C100
In stock
0.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product